Advanced Squamous Cell Carcinoma of the Lung

Is the Time Now?

Program Goals

Introduction

Parsing Lung Cancer to Optimize Patient Management

Recommendations From NCCN NSCLC Guidelines

Recommendations From NCCN NSCLC Guidelines (cont)

Nab-paclitaxel vs Solvent-based Paclitaxel in First-line

ChemotherapyEfficacy Results

Second-line Therapy Options Are Limited in Advanced NSCLC

Targetable Molecular Alterations in Nonsquamous Advanced NSCLC

Potential Targetable Molecular Alterations in Advanced NSCLC,

SCC

SWOG S1400: Lung-MAP Study

Antibody Therapy in Advanced NSCLC, Including SCC

REVELStudy Design

REVEL: PFS

REVELForest Plot of PFS by Histologic Subgroup

REVELForest Plot of OS by Histologic Subgroup

REVELBleeding-related AEs

Phase 3 Trials of Cetuximab in Advanced NSCLC

SQUIREStudy Design

SQUIREForest Plot of OS by Subgroup

SQUIREExploratory Analysis of EGFR H-Score

SQUIRE: AEs

Role of CTLA-4 in the Immune Response

Role of PD-1/PD-L1 in the Immune Response

Immune System in Carcinogenesis

Ipilimumab + Chemotherapy in Advanced NSCLCDesign of Phase 2 Trial

Ipilimumab + Chemotherapy in Advanced NSCLC

Results

Ipilimumab + ChemotherapyHistology Subgroup Analysis

Phase 1 Study of Nivolumab in Heavily Pretreated Pts With

Advanced NSCLCHistology Subgroup Analysis

Recurrent NSCLC, SCC Single-agent Nivolumab Therapy

Relationship Between PD-L1 Tumor Status and Response to MK-3475

Pretreated Advanced NSCLC

Clinical Development of Some PD-1/PD-L1 Immune Checkpoint

Inhibitors

First-line MK 3475 in Advanced NSCLC

Study Design

First-line MK 3475 in Advanced NSCLC

Efficacy Results

ASCO PerspectiveDefining Clinically Meaningful Outcomes in Lung

Cancer Clinical Trials

Summary: Advanced NSCLC, SCC

Abbreviations

Abbreviations (cont)

Abbreviations (cont)

References

References (cont)

References (cont)

References (cont)

References (cont)

References (cont)

References (cont)

References (cont)

References (cont)